Kyoko Ohno-Matsui教授是全球公认的病理性近视研究领域顶尖专家，现任东京医科齿科大学（TMDU）眼科与视觉科学系教授兼系主任及该校先进近视临床中心主任。她长期致力于病理性近视发病机制的研究，并开发创新的诊断与治疗技术。

Kyoko Ohno-Matsui教授率先使用“3D核磁共振成像技术（MRI）”，可视化病理性近视患者整个眼球形态，揭示该疾病的本质是后部眼球变形相关病变。她还主导研发了超广角OCT及偏振敏感OCT技术，用于研究后部疱状突起及巩膜微结构的变化。此外，她深入探索病理性近视的遗传性异质性，并发现其与Alport综合征相关变异的关联。

Kyoko Ohno-Matsui教授发表了大量高影响力学术论文，并多次受邀在国际主要眼科学大会上作主旨演讲。她牵头开展多项国际合作与共识项目，在全球近视研究领域发挥着重要引领作用。作为国内外学术界活跃成员，她担任日本近视学会主席、国际近视学会主席以及多个学术组织的理事，积极推动全球病理性近视的临床和研究发展。

Professor Kyoko Ohno-Matsui is globally recognized as a leading expert in the field of pathological myopia research. She currently serves as Professor and Chair of the Department of Ophthalmology and Visual Science at Tokyo Medical and Dental University (TMDU) and is the Director of the Advanced Clinical Center for Myopia at the same institution. She has long been dedicated to studying the pathogenesis of pathological myopia and developing innovative diagnostic and therapeutic techniques.

Professor Kyoko Ohno-Matsui pioneered the use of "three-dimensional magnetic resonance imaging (3D MRI)" to visualize the entire ocular morphology in patients with pathological myopia, revealing that the disease is fundamentally related to posterior ocular deformation. She also led the development of ultra-widefield OCT and polarization-sensitive OCT technologies to study posterior staphyloma and changes in scleral microstructure. Furthermore, she has extensively explored the genetic heterogeneity of pathological myopia and discovered its association with variants related to Alport syndrome.

Professor Kyoko Ohno-Matsui has published numerous high-impact academic papers and has been frequently invited to deliver keynote speeches at major international ophthalmology conferences. She has spearheaded multiple international collaborations and consensus projects, playing a pivotal leadership role in global myopia research. As an active member of the academic community both domestically and internationally, she serves as President of the Japan Myopia Society, President of the International Myopia Society, and holds council positions in several academic organizations, actively advancing the clinical and research development of pathological myopia worldwide.